According to health experts, if you eat the right foods, your body will trigger the natural release of GLP-1 – which is what ...

Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease ...

Recent research easing suicidality concerns about GLP-1s and suggesting potential psychiatric benefit has led to a call for ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

A new study suggests semaglutide drugs like Ozempic, used for type 2 diabetes, may lower the risk of opioid overdose in ...

Indian shares are set to open at fresh highs on Friday, riding the coattails of the outsized U.S. rate cut last week, with IT ...

Wegovy is a once-weekly injection approved by the U.S. Food and Drug Administration (FDA) to treat obesity in people 12 and ...

Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

to examine potential applications of glucagon-like peptide-1 receptor (GLP-1R) agonists in central nervous system disorders, such as dementia, Parkinson’s disease, substance and alcohol use disorders, ...

Infosys announced strategic collaboration with Sally Beauty to bring enterprise scale IT efficiencies from hyper automation.